Actively Recruiting
Liposomal Bupivacaine and Bupivacaine for TTMPB in Median Sternotomy
Led by Tongji Hospital · Updated on 2024-10-28
38
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In light of the ongoing controversy surrounding the efficacy of bupivacaine liposomes, our study was designed to investigate, for the first time, the differential postoperative analgesic effects between bupivacaine liposomes combined with bupivacaine hydrochloride and bupivacaine hydrochloride alone in transverse thoracic muscle plane block treatment. The aim is to provide evidence-based medical guidance for drug selection in regional block local anesthesia.
CONDITIONS
Official Title
Liposomal Bupivacaine and Bupivacaine for TTMPB in Median Sternotomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 90 years
- ASA Class I to III
- Patients undergoing elective median sternotomy
You will not qualify if you...
- Emergency surgery
- Re-operation
- Coagulation dysfunction
- Poor preoperative left ventricular function (ejection fraction <35%)
- Systemic infection or injection site infection
- Neuromuscular diseases
- Mental illness
- Dependence on psychotropic drugs
- Allergy to bupivacaine liposomes or bupivacaine
- Prior participation in similar trials or deemed unsuitable for randomization
- Failure to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianzhu Liu
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
L
Liu Tianzhu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here